Abstract
Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.
Original language | English |
---|---|
Pages (from-to) | S30 |
Journal | BMC Public Health |
Volume | 11 Suppl 3 |
DOIs | |
Publication status | Published - 2011 |